Learn More
Invitrogen™ beta Amyloid Recombinant Rabbit Monoclonal Antibody (H31L21)
Description
Cross reactivity to Abeta [1-40] is not observed in sandwich ELISA. In addition, in antigen ELISA cross-reactivity is not observed with Abeta [1-37], Abeta [1-38], Abeta [1-40], or Abeta [1-43] when used at low antibody concentrations (up to 30 ng/mL). Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
Specifications
Specifications
| Antigen | beta Amyloid |
| Applications | ELISA, Immunohistochemistry (Paraffin) |
| Classification | Recombinant Monoclonal |
| Clone | H31L21 |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.09% sodium azide |
| Gene | APP |
| Gene Accession No. | P05067, P12023 |
| Gene Alias | A4; AAA; ABETA; Abeta40; Abeta42; ABPP; AD1; Adap; AG; AICD-50; AICD-57; AICD-59; AID(50); AID(57); AID(59); Alpha-CTF; Alpha-secretase C-terminal fragment; Alzheimer disease; Alzheimer disease amyloid A4 protein homolog; alzheimer disease amyloid protein; Amyloid; amyloid A4; Amyloid b; Amyloid beta; amyloid beta (A4) precursor protein; amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease); amyloid beta A4 protein; amyloid beta precursor protein; Amyloid intracellular domain 50; Amyloid intracellular domain 57; Amyloid intracellular domain 59; Amyloid precursor protein; amyloid precursor protein variant 1; amyloid precursor protein variant 2; Amyloid β; amyloid-beta A4 protein; amyloid-beta A4 protein; amyloid beta A4 protein; Amyloid-beta precursor protein; Amyloid-beta protein 40; Amyloid-beta protein 42; Amyloidogenic glycoprotein; APP; APP-C57; APP-C59; APP-C99; APPI; appican; beta amyloid protein; beta amyloid protein precursor; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); Beta-amyloid precursor protein; betaApp; Beta-APP40; Beta-APP42; Beta-CTF; Beta-secretase C-terminal fragment; C31; C80; C83; C99; Cerebral vascular amyloid peptide; CTF gamma; CTF-alpha; CTFgamma; CVAP; E030013M08Rik; Gamma-CTF(50); Gamma-CTF(57); Gamma-CTF(59); Gamma-secretase C-terminal fragment 50; Gamma-secretase C-terminal fragment 57; Gamma-secretase C-terminal fragment 59; N-APP; OTTHUMP00000096096; P3(40); P3(42); Pan-Abeta; peptidase nexin-II; PN2; PN-II; PreA4; PreA4 751; protease nexin II; protease nexin-II; S-APP-alpha; S-APP-beta; Soluble APP-alpha; Soluble APP-beta; testicular tissue protein Li 2 |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.